Improving Lives by Improving Blood Flow™

BUY D'OXYVA

Investor Relations

According to the CEO of a global clinical research organization and other experts, Circularity Healthcare's upcoming pivotal clinical trial report is expected to catapult its valuation to several billions of dollars.

Circularity is expanding its operations with a platform noninvasive transdermal drug-device product called D’OXYVA®, which is in expanded pivotal trials at 18 of the 20 top-ranked U.S. universities for an updated FDA clearance for becoming a universal treatment for the diabetic foot ulcer epidemic.
Play Video about D'OXYVA Groundbreaking FDA-approved, Rapid, Pain-Free Diabetic Wound Treatment video overlay
PHYSICIAN-RECOMMENDED, EASY TO USE DAILY

Recognize & Improve Poor Circulation

Poor circulation has the potential to deliver a variety of unpleasant consequences — from banal muscle pains to the potential development of gangrene.

“Throughout the world, it is estimated that every 30 seconds a leg is amputated. And 85% of these amputations were the result of a diabetic foot ulcer.” – Foluso A. Fakorede, MD

Amputation might be necessary for as high as 43% of patients diagnosed with Diabetic Foot Ulcer (DFU) within 1-4 years at a cost of thousands of dollars. DFU and its standard treatment results in lower productivity of the patient, reduced quality of life, physical and emotional burden to loved ones and a huge financial cost that can reach tens of thousands of dollars annually on average.

The U.S. has the highest incidence rates for DFU with the highest cost, while the number of patients is expected to keep growing for the foreseeable future. 

Highlights

  • D’OXYVA® will be the first drug–device combination in the market for treating DFU.
 
 
  • IP is fully owned by Circularity.
 
 
  • Circularity has the world’s first FDA-approved mini cartridge in exclusive production by a major global specialty pharmaceutical manufacturer.
 
 
  • Product is market-proven in North-America, Asia and Europe as acceptable and true to promise.
 
 
  • Hospitals are ready to adopt products once full FDA approval is acquired.
 
 
  • Commercialization is well-underway in over two-dozen countries.
 
 
  • Circularity is led by a globally experienced team with proven track records in business and healthcare.

D’OXYVA® (deoxyhemoglobin vasodilator) achieves consistent and powerful results by significantly improving healing time, reducing long-term pain, and lowering the cost of treatment of this epidemic, while providing a massive return for investors as well.

Circularity Healthcare, LLC is a decade-old, revenue-stage, private company in the final stages of obtaining updated FDA approval for D’OXYVA through expanded pivotal trials with the assistance of most Ivy League colleges, a global clinical research organization (CRO) and a global law firm on its currently approved platform drug and move the product to the U.S. market, which will be its biggest market.

The global diabetic foot ulcer treatment market was valued at over $8.7 billion in 2020 and is predicted to reach $12.3 billion by 2026, rising at a remarkable 7.9% CAGR between 2021 and 2026, according to Facts and Factors.

GET YOUR D’OXYVA
diabetic-foot-ulcers-treatment-market-infographic
ADD D’OXYVA TO YOUR DAILY LIVING TODAY!

5-Part Regimen To Improve Circulation

D’OXYVA® – a patented, world’s first noninvasive, clinically-tested, regenerative transdermal drug delivery product with an FDA-approved platform non-toxic drug is about to disrupt the industry by radically changing the standard of care and become the universal treatment for the epidemic of diabetic wounds or diabetic foot ulcers (DFU).

D’OXYVA’s mechanism of action is unique — life-restoring ultra-purified, FDA-approved, molecular carbon dioxide (CO2) and gentle vapor dissolves across the skin to act as a messenger (gasotransmitter) for significantly improving rest and digest (parasympathetic) nerve functions, skin perfusion pressure (microcirculation) and many other changes to achieve, maintain and further improve physiological balance (homeostasis) and performance.

The three main cycles of D’OXYVA’s regimen is: Treatment, Improvement, Preventive.

D’OXYVA works especially well on mild-to-severe spider veins, varicose veins, ‘non-healing’ chronic wounds, long-term pain, severe diabetic, cardiovascular, neurological and autoimmune complications.

D’OXYVA will radically change the cost of care by 20-100X and will deliver 2-3X faster results with no prospects of patient readmission into the hospital. Pivotal trial and other studies showed 1-2 weeks pain relief, 1-2 months healing, 3-4 months amputation prevention, 6-9 months survival benefit. Studies demonstrated a prolonged progression-free result and overall survival with zero or acceptable toxicity.

Have you found anything safer and more effective? We would love to know – contact us.

Did you know? Most Frequently Administered Drugs in the U.S. Are Not What You Think!

Add these foods to increase proper blood flow.

• Onion and garlic

• Dark chocolate

• Citrus foods

• Chili powder

• Olive oil

• Nuts and seeds

These vitamins may improve circulatory health.

• Niacin

• Vitamin E

• Ascorbic acid

• Vitamin K

Moderate exercise helps to improve overall blood flow.

• Walking and jogging

• Light weightlifting

• Aerobics and yoga

• Swimming

Essential changes you can make to improve circulation.

• Stretching any time of day

• Quitting smoking

• Getting regular massages

• Resting with feet above head

• Drinking more water

Adding the D’OXYVA biotech solution to the above recommended regimen can literally transform your physical condition and mental well-being, resulting in a total enhancement of your quality of life.

spotlight-3
WE BELIEVE IN REAL HEALTH CARE

Experience The Healing Powers Of Microcirculation

D’OXYVA® (deoxyhemoglobin vasodilator) is the pioneering non-invasive biotech solution created by the health science experts at Circularity Healthcare – validated to deliver a wealth of health, athletic, and cosmetic benefits in a single pain-free, convenient, and affordable application.

Now, Circularity is seeking investment to complete its expanded pivotal trial and ramp up sales and marketing operations spanning four continents.

By our modest projections, introducing D’OXYVA into the market has a revenue potential of over $400 million dollars annually.

All stakeholders are on board with our pivotal clinical trials, while being confident in a positive outcome within a few months.


Innovative global multinationals and large hospital networks covering millions of patients are ready to procure D’OXYVA.


More information can be found in an investor presentation upon request.


We look forward to your investment to help push this product to market as fast as possible.

CONTACT US
Family measuring D'Oxyva perfusion index (peripheral blood circulation), oxygen saturation, heart rate, repsiratory rate results with oximeter

Hold Your Loved Ones Accountable With Instant Proof It's Working

ORDER SET & GET YOUR FREE OXIMETER*
Family measuring D'Oxyva perfusion index (peripheral blood circulation), oxygen saturation, heart rate, repsiratory rate results with oximeter

The finger pulse oximeter demonstrates D’OXYVA® results in under one minute. It accurately measures pulse rate, peripheral blood flow (PI), and oxygen saturation via the finger. Designed with the most straightforward operation in mind, it utilizes self-adjusting finger clips and a single-button function.

Cardiac patients and those who have circulatory pathologies will find the finger pulse oximeter to be an invaluable tool for monitoring their conditions.

*Free Finger Tip Pulse Oximeter for a limited time when you purchase D'OXYVA

ORDER SET & GET YOUR FREE OXIMETER*

Surgery vs. Nonsurgery

Comparing Options

Surgery

  • SAFETY Surgery is associated with significant post-treatment complications.
  • OUTCOMES Invasive surgeries for varicose veins require considerably longer time for post-surgical recovery. Prognosis is often affected by super-imposed complications.
  • RECURRENCE Recurrence of the problem after surgical management is about 50% within 5 years.
  • CONVENIENCE Surgeries for varicose veins require considerable pre, and post-surgical care.
  • COMPLICATIONS Surgeries often lead to unwanted complications like blood clots, suture failure and infections.
  • COST Surgeries for varicose veins cost a fortune and that come with more risks of complications.

Nonsurgery

  • SAFETY Non-invasive solutions for varicose veins are much safer compared to surgical options.
  • OUTCOMES In almost 95% of cases, non-invasive options show nearly 100% efficacy. 
  • RECURRENCE When managed properly, non-surgical options result in permanent recovery from varicose veins.
  • CONVENIENCE Non-invasive options for varicose veins are more convenient and no special medical assistance is required.
  • COMPLICATIONS Non-invasive management of varicose veins doesn’t result in significant complications.
  • COST The cost of non-invasive solutions for varicose veins is much lower than the surgical interventions.

What Our Customers Say

Caroline
Caroline
U.S.A.
Read More
"I could not believe how my big, bulging spider veins on my leg had faded in a couple of weeks then nearly disappeared in about a couple of months. No more pain either! Thank you, D'OXYVA!"
Leroy
Leroy
U.S.A.
Read More
"This gadget is amazing! It really helped reduce my back pain and my Covid-19 symptoms in a few days. Absolutely love it!"
PBranham
PBranham
U.S.A.
Read More
"Love my D'OXYVA. Everyone needs this to stay fit and healthy and above all, stay in shape with a healthy weight. It only takes a few minutes a day. Must try!"
Previous
Next
MORE REVIEWS

From Our Blog

D'OXYVA logo